X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AUM001 is a mRNA translation inhibitor that targets MNK 1/2 and the chokepoint of multiple pro-oncogenic signalling pathways, being investigated for the treatment of metastatic colorectal cancer.
Lead Product(s): AUM001,Pembrolizumab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: AUM001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
AUM302 is a potential oral kinase inhibitor, combines with pan-PIM kinase, pan-PI3K and mTOR inhibition in single agent. It has the potential to inhibit multiple key intracellular pathways, increasing its ability to inhibit cancer cell growth and prevent resistance emergence.
Lead Product(s): AUM302
Therapeutic Area: Oncology Product Name: AUM302
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
AUM302 is a potential first-in-class oral kinase inhibitor rationally designed to uniquely combine pan-PIM kinase, pan-PI3K and mTOR inhibition in a single agent. AUM302 has shown promise with good tolerability and favourable drug properties.
Lead Product(s): AUM302
Therapeutic Area: Oncology Product Name: AUM302
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
AUM001 is highly selective translation inhibitor. In vitro, it was observed to selectively inhibit MAPK – interacting protein kinase (MNK) types 1/2 and is expected to thereby block phosphorylation of eIF4E, and in turn, interfere with CAP mediated RNA translation.
Lead Product(s): AUM001,Pembrolizumab
Therapeutic Area: Oncology Product Name: AUM001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2022
Details:
AUM001 is a selective and synergistic MNK inhibitor as shown in current studies and expected to begin Phase 2 enrollment in the fourth quarter 2022. AUM601 is a promising therapy for TRK fusions and mutations within the kinase domain and is on track to enter Phase 2.
Lead Product(s): AUM001,Pembrolizumab
Therapeutic Area: Oncology Product Name: AUM001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mountain Crest Acquisition Corp. V
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 20, 2022
Details:
AUM601 is a highly selective, oral small molecule that inhibits not only pan-TRK (TRKA, TRKB, and TRKC), but also resistance mutations of TRKs, by blocking the activity of tyrosine kinases.
Lead Product(s): AUM601
Therapeutic Area: Oncology Product Name: AUM601
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
As a result, AUM plans to evaluate AUM001, in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab), in a global Phase 2 clinical trial in patients with microsatellite stable colorectal cancer (MSS CRC).
Lead Product(s): AUM001,Pembrolizumab
Therapeutic Area: Oncology Product Name: AUM001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
This collaboration with MSD marks a major milestone and enables the joint clinical development of AUM001 in combination with KEYTRUDA. As a monotherapy, AUM001 demonstrated encouraging safety, tolerability and target engagement in two Phase 1 studies.
Lead Product(s): AUM001,Pembrolizumab
Therapeutic Area: Oncology Product Name: AUM001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 05, 2022
Details:
AUM-601 (CHC2014), a selective second-generation “Pan-TRK” Inhibitor was safe and well-tolerated at dose levels of 50 to 300 mg QD, as recommend Phase 2 dose (RP2D) based on PK profile and safety results.
Lead Product(s): CHC2014
Therapeutic Area: Oncology Product Name: AUM601
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: HANDOK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
Under the terms of the agreement, AUM and Asymchem agree to collaborate on the process development, and the clinical and commercial production, of AUM 601, which is a highly selective oral small-molecule inhibitor of the tropomyosin receptor kinase for treating rare cancers.
Lead Product(s): AUM601
Therapeutic Area: Oncology Product Name: AUM601
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Asymchem Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
